Description: Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Home Page: www.tricida.com
7000 Shoreline Court
South San Francisco,
CA
94080
United States
Phone:
415 429 7800
Officers
| Name | Title |
|---|---|
| Dr. Gerrit Klaerner Ph.D. | Founder, Pres, CEO & Exec. Director |
| Mr. Geoffrey M. Parker | COO, CFO & Exec. VP |
| Mr. Robert L. McKague J.D. | Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer |
| Dr. Dawn Parsell Ph.D. | Exec. VP of Clinical Devel. |
| Ms. Annie Yoshiyama | VP of Fin. & Chief Accounting Officer |
| Jackie Cossmon | VP of Investor Relations & Communications |
| Mr. Edward J. Hejlek Esq., J.D. | Exec. VP of Intellectual Property |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2122.0897 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 57 |